BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 17.7] [Reference Citation Analysis]
Number Citing Articles
1 Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. Expert Opinion on Pharmacotherapy 2017;18:743-51. [DOI: 10.1080/14656566.2017.1317748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Mikolasevic I, Milic S, Filipec-Kanizaj T. Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation. Liver Int. 2017;37:1113-1115. [PMID: 28710818 DOI: 10.1111/liv.13453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
4 Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ, Faraj W. Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. Ann Med Surg (Lond) 2020;57:166-70. [PMID: 32774848 DOI: 10.1016/j.amsu.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 de Barros F, Fonseca ABM. Bariatric surgery during the evolution of fatty liver-A randomized clinical trial comparing gastric bypass and sleeve gastrectomy based on transient elastography. Clin Obes 2020;10:e12393. [PMID: 32885600 DOI: 10.1111/cob.12393] [Reference Citation Analysis]
6 Eilenberg M, Munda P, Stift J, Langer FB, Prager G, Trauner M, Staufer K. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr 2021;10:610-22. [PMID: 34760965 DOI: 10.21037/hbsn-20-787] [Reference Citation Analysis]
7 Handzlik G, Holecki M, Kozaczka J, Kukla M, Wyskida K, Kędzierski L, Pawlicki K, Duława J. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacol Rep 2019;71:183-8. [PMID: 30780126 DOI: 10.1016/j.pharep.2018.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ehrampoush E, Ghaemi A, Osati S, Maleki M, Raeisi Shahraki H, Honarvar B, Bahmanyar M, Homayounfar R. The Association Between Serum Vitamin D Level and Nonalcoholic Fatty Liver Disease. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.92992] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 McKay A, Pantoja C, Hall R, Matthews S, Spalding P, Banerjee R. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. J Patient Rep Outcomes 2021;5:89. [PMID: 34508298 DOI: 10.1186/s41687-021-00363-5] [Reference Citation Analysis]
10 Kamali L, Adibi A, Ebrahimian S, Jafari F, Sharifi M. Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver. Adv Biomed Res 2019;8:69. [PMID: 31897407 DOI: 10.4103/abr.abr_114_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
12 Poul SS, Parker KJ. Fat and fibrosis as confounding cofactors in viscoelastic measurements of the liver. Phys Med Biol 2021;66:045024. [PMID: 33348325 DOI: 10.1088/1361-6560/abd593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Wáng YX, Idée JM. A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. Quant Imaging Med Surg 2017;7:88-122. [PMID: 28275562 DOI: 10.21037/qims.2017.02.09] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 20.8] [Reference Citation Analysis]
14 Duseja A, Chahal GS, Jain A, Mehta M, Ranjan A, Grover V. Association between nonalcoholic fatty liver disease and inflammatory periodontal disease: A case‑control study. J Indian Soc Periodontol 2021;25:47-54. [PMID: 33642741 DOI: 10.4103/jisp.jisp_45_20] [Reference Citation Analysis]
15 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, Zhao Y, He Y. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:43. [PMID: 33509116 DOI: 10.1186/s12876-021-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2022. [PMID: 35005800 DOI: 10.1111/apt.16766] [Reference Citation Analysis]
18 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 46.0] [Reference Citation Analysis]
19 Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics 2020;10:4277-89. [PMID: 32226553 DOI: 10.7150/thno.40249] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
20 Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep 2020;10:21117. [PMID: 33273703 DOI: 10.1038/s41598-020-78342-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
21 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhães J, Moreira MJ, Marinho C, Cotter J. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. Eur J Gastroenterol Hepatol 2019;31:998-1003. [PMID: 30839437 DOI: 10.1097/MEG.0000000000001319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Hepkema JT, Poelmann FB, Gouw ASH, de Haas RJ, Duiker EW, Blokzijl H, Klaase JM. Malignant Transformation of an HNF1a-Inactivated Hepatocellular Adenoma to Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:577-85. [PMID: 33250700 DOI: 10.1159/000510215] [Reference Citation Analysis]
24 Hu YY, Dong NL, Qu Q, Zhao XF, Yang HJ. The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. Medicine (Baltimore) 2018;97:e12931. [PMID: 30412101 DOI: 10.1097/MD.0000000000012931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
26 Li Y, Liu S, Gao Y, Ma H, Zhan S, Yang Y, Xin Y, Xuan S. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. BMC Biochem 2019;20:3. [PMID: 30727943 DOI: 10.1186/s12858-019-0106-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
28 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
29 Ruzman L, Mikolasevic I, Baraba Dekanic K, Milic S, Palcevski G. Advances in diagnosis of chronic liver diseases in pediatric patients. World J Pediatr 2018;14:541-7. [DOI: 10.1007/s12519-018-0197-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Han K, Kwon O, Park HJ, Jung SY, Yang C, Son CG. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. Trials 2020;21:128. [PMID: 32005283 DOI: 10.1186/s13063-020-4068-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Mikolasevic I, Stojsavljevic S, Blazic F, Mijic M, Radic-Kristo D, Juric T, Skenderevic N, Klapan M, Lukic A, Filipec Kanizaj T. Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand? World J Transplant 2021; 11(3): 37-53 [PMID: 33816145 DOI: 10.5500/wjt.v11.i3.37] [Reference Citation Analysis]
32 Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30. [DOI: 10.1038/s41575-019-0169-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 21.7] [Reference Citation Analysis]
33 Käräjämäki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Annals of Medicine 2018;50:371-80. [DOI: 10.1080/07853890.2018.1492147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
34 Samejo SA, Abbas Z, Asim M. Effects of anthropometric and metabolic parameters on transaminase levels and liver stiffness in patients with non-alcohol fatty liver disease. Trop Doct 2021;51:185-9. [PMID: 33040692 DOI: 10.1177/0049475520962742] [Reference Citation Analysis]
35 Dehnavi Z, Razmpour F, Belghaisi Naseri M, Nematy M, Alamdaran SA, Vatanparast HA, Azimi Nezhad M, Abbasi B, Ganji A. Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD). Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.63227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
36 Weiskirchen R, Tacke F. The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Curr Hepatology Rep 2018;17:324-35. [DOI: 10.1007/s11901-018-0421-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Castro PCS, Alberton HCP, Pedroso MLA, Morsoletto DBG, Pissaia Junior A, Ivantes CAP. EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS. Arq Gastroenterol 2019;56:256-60. [PMID: 31633721 DOI: 10.1590/S0004-2803.201900000-48] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Elkabany ZA, Hamza RT, Ismail EAR, Elsharkawy A, Yosry A, Musa S, Khalaf MA, Elgawesh RM, Esmat G. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. Eur J Gastroenterol Hepatol 2020;32:1008-16. [PMID: 31834057 DOI: 10.1097/MEG.0000000000001608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
39 Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018;48:821-828. [PMID: 29679473 DOI: 10.1111/hepr.13179] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
40 Gao B, Emami A, Zhou R, Lang S, Duan Y, Wang Y, Jiang L, Loomba R, Brenner DA, Stärkel P, Schnabl B. Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Front Physiol 2020;11:370. [PMID: 32390870 DOI: 10.3389/fphys.2020.00370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Chayanupatkul M, Dasani DB, Sogaard K, Schiano TD. The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. Transplant Proc. 2020;. [PMID: 32434740 DOI: 10.1016/j.transproceed.2020.02.160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329-41. [PMID: 32039383 DOI: 10.1016/j.jhepr.2019.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
43 Mandelia C, Kabbany MN, Worley S, Conjeevaram Selvakumar PK. Performance Characteristics, Intra- and Inter-operator Agreement of Transient Elastography in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2021;72:430-5. [PMID: 33230078 DOI: 10.1097/MPG.0000000000002991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Alsaif FA, Alqahtani SH, Alsadoon AM, Alswat KA, Abdo AA, Hassanain MM, Alsharabi AB, Aljuhani GR, Alkhalidi HM, Elsharkawy MS, Alotaibi MA, Sanai FM, Al-Hamoudi WK. Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease. Saudi J Gastroenterol. 2020;. [PMID: 32341228 DOI: 10.4103/sjg.sjg_29_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Patel P, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Bernard A, Brown NN, Lampe G, Buck L, Saad N, Russell AW, Valery PC, Irvine KM, Clouston AD, Stuart KA, Rosenberg W, Powell EE. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. Hepatol Commun 2018;2:893-905. [PMID: 30094401 DOI: 10.1002/hep4.1208] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
46 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24(11): 1269-1277 [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
47 Mandelia C, Kabbany MN, Conjeevaram Selvakumar PK, Alkhouri N. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. Biomark Med 2018;12:265-73. [PMID: 29517271 DOI: 10.2217/bmm-2017-0038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
48 Mathew RP, Venkatesh SK. Imaging of Hepatic Fibrosis. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0652-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
49 Yang X, Chang X, Wu S, Sun X, Zhu X, Wang L, Xu Y, Yao X, Rao S, Hu X, Xia M, Bian H, Yan H, Gao X. Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease. Lipids Health Dis 2021;20:27. [PMID: 33757528 DOI: 10.1186/s12944-021-01453-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ferguson AE, Xanthakos SA, Siegel RM. Challenges in Screening for Pediatric Nonalcoholic Fatty Liver Disease. Clin Pediatr (Phila) 2018;57:558-62. [DOI: 10.1177/0009922817733300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Lin Y, Wan Y, Tai D, Tseng J, Wang C, Tsai Y, Lin Y, Chang T, Tsui P. Considerations of Ultrasound Scanning Approaches in Non-alcoholic Fatty Liver Disease Assessment through Acoustic Structure Quantification. Ultrasound in Medicine & Biology 2019;45:1955-69. [DOI: 10.1016/j.ultrasmedbio.2019.04.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
52 Zeng Q, Song Z, Zhao Y, Wu J, Wang L, Ye H, Wang Y, Wu T, Yuan S, Yuan H. Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction. Hepatol Res 2020;50:578-87. [PMID: 31883216 DOI: 10.1111/hepr.13481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Bullón-vela MV, Abete I, Alfredo Martínez J, Angeles Zulet M. Obesity and Nonalcoholic Fatty Liver Disease. Obesity. Elsevier; 2018. pp. 111-33. [DOI: 10.1016/b978-0-12-812504-5.00006-4] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mak AL, Lee J, van Dijk AM, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1920. [PMID: 34944736 DOI: 10.3390/biomedicines9121920] [Reference Citation Analysis]
55 Didoné Filho CN, Reginatto CJ, Ivantes CAP, Strobel R, Percicote AP, Petenusso M, Sobreira da Silva CJR, Benjamim CJR, Radominski RB. Comparison between non-invasive methods and liver histology to stratify liver fibrosis in obese patients submitted to bariatric surgery. Obes Res Clin Pract 2021;15:152-6. [PMID: 33648885 DOI: 10.1016/j.orcp.2021.02.004] [Reference Citation Analysis]
56 Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:128-41. [PMID: 31696690 DOI: 10.3350/cmh.2019.0001n] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
57 Çevik Saldiran T, Mutluay FK, Yağci İ, Yilmaz Y. Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. Ann Endocrinol (Paris) 2020;81:493-9. [PMID: 32768394 DOI: 10.1016/j.ando.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
58 Chi-Cervera LA, Montalvo GI, Icaza-Chávez ME, Torres-Romero J, Arana-Argáez V, Ramírez-Camacho M, Lara-Riegos J. Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®). J Med Biochem 2021;40:60-6. [PMID: 33584141 DOI: 10.5937/jomb0-24689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. Medicine (Baltimore) 2019;98:e16018. [PMID: 31277096 DOI: 10.1097/MD.0000000000016018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019;. [PMID: 31786361 DOI: 10.1016/j.diabet.2019.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
61 Lv DD, Wang YJ, Wang ML, Chen EQ, Tao YC, Zhang DM, Tang H. Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B. Sci Rep 2021;11:655. [PMID: 33436935 DOI: 10.1038/s41598-020-80709-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Pasanta D, Htun KT, Pan J, Tungjai M, Kaewjaeng S, Kim H, Kaewkhao J, Kothan S. Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. Diagnostics (Basel) 2021;11:842. [PMID: 34067193 DOI: 10.3390/diagnostics11050842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kwak M, Chung GE, Yang JI, Yim JY, Chung SJ, Jung SY, Kim JS. Clinical implications of controlled attenuation parameter in a health check-up cohort. Liver Int 2018;38:915-23. [DOI: 10.1111/liv.13558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
64 MacCurtain BM, Quirke NP, Thorpe SD, Gallagher TK. Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis. J Clin Med 2021;10:2711. [PMID: 34205335 DOI: 10.3390/jcm10122711] [Reference Citation Analysis]
65 Lin YH, Liao YY, Yeh CK, Yang KC, Tsui PH. Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome. Entropy (Basel) 2018;20:E893. [PMID: 33266617 DOI: 10.3390/e20120893] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
66 Yao QY, Feng YD, Han P, Yang F, Song GQ. Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients. World J Gastroenterol 2020; 26(27): 3917-3928 [PMID: 32774066 DOI: 10.3748/wjg.v26.i27.3917] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Mikolasevic I, Lukenda Zanko V, Jakopcic I, Domislovic V, Mijic A, Stevanovic T, Delija B, Bokun T, Dinjar Kujundzic P, Ostojic A, Filipec Kanizaj T, Grgurevic I, Krznaric Z, Stimac D, Targher G. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. J Diabetes Complications 2020;34:107512. [PMID: 31882273 DOI: 10.1016/j.jdiacomp.2019.107512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
68 Pisetta C, Chillè C, Pelizzari G, Pigozzi MG, Salvetti M, Paini A, Muiesan ML, De Ciuceis C, Ricci C, Rizzoni D. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease. High Blood Press Cardiovasc Prev 2020;27:321-30. [DOI: 10.1007/s40292-020-00389-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Syed T, Chadha N, Kumar D, Gupta G, Sterling RK. Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. Gastroenterology Res 2021;14:244-51. [PMID: 34527094 DOI: 10.14740/gr1445] [Reference Citation Analysis]
70 Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Sophonphan J, Trinavarat P, Visrutaratna P, Srinakarin J, Chaijitraruch N, Puthanakit T; NAFLD Study Group. Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. PLoS One 2019;14:e0226375. [PMID: 31856189 DOI: 10.1371/journal.pone.0226375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Swelam A, Adam R, Lauka L, Basilio Rodrigues L, Elgarf S, Sebagh M, Golse N, Sa Cunha A, Cherqui D, Castaing D, Allard MA. A Model to Predict Significant Macrosteatosis in Hepatic Grafts. World J Surg 2020;44:1270-6. [PMID: 31858179 DOI: 10.1007/s00268-019-05330-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, Singh S, Faulkner C, Richards L, Hester KD, Okada L, Li XJ, Mimms L, Abdelmalek MF. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2019;17:1867-1876.e3. [PMID: 30448594 DOI: 10.1016/j.cgh.2018.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
73 Tsunoda K, Kitano N, Kai Y, Jindo T, Uchida K, Arao T. Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:1330-9. [PMID: 34633105 DOI: 10.1111/apt.16631] [Reference Citation Analysis]
74 Tan YW, Zhou XB, Ye Y, He C, Ge GH. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase. World J Gastroenterol 2017; 23(31): 5746-5754 [PMID: 28883700 DOI: 10.3748/wjg.v23.i31.5746] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
75 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
76 Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K, Komolmit P, Tangkijvanich P, Rerknimitr R, Adams L, Treeprasertsuk S. Screening for non-alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter-transient elastography.JGH Open. 2020;4:245-250. [PMID: 32280772 DOI: 10.1002/jgh3.12252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Durazzo M, Marzari L, Bonetto S, Ferro A, Ghigo MC, Belci P, Collo A, Fagoonee S. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. Minerva Gastroenterol Dietol 2020;66:301-6. [PMID: 32700500 DOI: 10.23736/S1121-421X.20.02753-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Kamolvisit S, Chirnaksorn S, Nimitphong H, Sungkanuparph S. Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. Cureus 2021;13:e19046. [PMID: 34858740 DOI: 10.7759/cureus.19046] [Reference Citation Analysis]
79 Mikolasevic I, Hauser G, Mijic M, Domislovic V, Radic-Kristo D, Krznaric Z, Razov-Radas M, Pavic T, Matasin M, Filipec Kanizaj T. Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements. Can J Gastroenterol Hepatol 2021;2021:6657047. [PMID: 33628759 DOI: 10.1155/2021/6657047] [Reference Citation Analysis]
80 Morrill KE, Bland VL, Klimentidis YC, Hingle MD, Thomson CA, Garcia DO. Assessing Interactions between PNPLA3 and Dietary Intake on Liver Steatosis in Mexican-Origin Adults. Int J Environ Res Public Health 2021;18:7055. [PMID: 34280991 DOI: 10.3390/ijerph18137055] [Reference Citation Analysis]
81 Bastian WP, Hasan I, Lesmana CRA, Rinaldi I, Gani RA. Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases. Case Rep Gastroenterol 2019;13:125-33. [PMID: 31011312 DOI: 10.1159/000498946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
82 Park J, Lee JM, Lee G, Jeon SK, Joo I. Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. Korean J Radiol 2022;23:13-29. [PMID: 34983091 DOI: 10.3348/kjr.2021.0112] [Reference Citation Analysis]
83 Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis. 2017;8:e3135. [PMID: 29072690 DOI: 10.1038/cddis.2017.554] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
84 Kim HB, Lee YJ. Association of resting heart rate with nonalcoholic fatty liver disease in postmenopausal women. Medicine (Baltimore) 2020;99:e19529. [PMID: 32243369 DOI: 10.1097/MD.0000000000019529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Hou YG, Xu Y, Bao J, Hua J, Kang GL, Li QL. Factors affecting accuracy of controlled attenuation parameter by Fibrotouch in assessing hepatic steatosis. Shijie Huaren Xiaohua Zazhi 2017; 25(19): 1783-1787 [DOI: 10.11569/wcjd.v25.i19.1783] [Reference Citation Analysis]
86 Jongraksak T, Sobhonslidsuk A, Jatchavala J, Warodomwichit D, Kaewduang P, Sungkanuparph S. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. Int J STD AIDS 2021;32:266-75. [DOI: 10.1177/0956462420960997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Berdja S, Boudarene L, Smail L, Neggazi S, Boumaza S, Sahraoui A, Haffaf EM, Kacimi G, Aouichat Bouguerra S. Scolymus hispanicus (Golden Thistle) Ameliorates Hepatic Steatosis and Metabolic Syndrome by Reducing Lipid Accumulation, Oxidative Stress, and Inflammation in Rats under Hyperfatty Diet. Evid Based Complement Alternat Med 2021;2021:5588382. [PMID: 34335826 DOI: 10.1155/2021/5588382] [Reference Citation Analysis]
88 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
89 Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhães J, Marinho C, Pinto R, Costa W, Pinto Correia J, Cotter J. Transient elastography: should XL probe be used in all overweight patients? Scand J Gastroenterol 2019;54:1022-6. [PMID: 31322445 DOI: 10.1080/00365521.2019.1644367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
90 Barros BSV, Monteiro FC, Terra C, Gomes MB. Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. Diabetol Metab Syndr 2021;13:33. [PMID: 33741024 DOI: 10.1186/s13098-021-00649-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720. [PMID: 29073252 DOI: 10.1371/journal.pone.0186720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
92 Salva-Pastor N, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2019;194:105445. [PMID: 31381969 DOI: 10.1016/j.jsbmb.2019.105445] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
93 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
94 Mirizzi A, Franco I, Leone CM, Bonfiglio C, Cozzolongo R, Notarnicola M, Giannuzzi V, Tutino V, De Nunzio V, Bruno I, Buongiorno C, Campanella A, Deflorio V, Pascale A, Procino F, Sorino P, Osella AR. Effects of Some Food Components on Non-Alcoholic Fatty Liver Disease Severity: Results from a Cross-Sectional Study. Nutrients 2019;11:E2744. [PMID: 31726714 DOI: 10.3390/nu11112744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
95 Moret A, Boursier J, Houssel Debry P, Riou J, Crouan A, Dubois M, Michalak Provost S, Aubé C, Paisant A. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis. Ultraschall Med 2020. [PMID: 32992377 DOI: 10.1055/a-1233-2290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Mikolasevic I, Poropat G, Filipec Kanizaj T, Skenderevic N, Zelic M, Matasin M, Vranic L, Kresovic A, Hauser G. Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. Can J Gastroenterol Hepatol 2021;2021:6670065. [PMID: 33688490 DOI: 10.1155/2021/6670065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Adrian T, Sørensen IMH, Knop FK, Bro S, Ballegaard ELF, Nordestgaard BG, Fuchs A, Kofoed KF, Kühl JT, Sigvardsen PE, Hornum M, Feldt-Rasmussen B. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrol Dial Transplant 2021:gfab266. [PMID: 34505899 DOI: 10.1093/ndt/gfab266] [Reference Citation Analysis]
98 Kühn T, Nonnenmacher T, Sookthai D, Schübel R, Quintana Pacheco DA, von Stackelberg O, Graf ME, Johnson T, Schlett CL, Kirsten R, Ulrich CM, Kaaks R, Kauczor HU, Nattenmüller J. Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. BMC Gastroenterol 2018;18:113. [PMID: 30005625 DOI: 10.1186/s12876-018-0840-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
99 Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, Javedan G, Ehrampoush E, Homayounfar R. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS One 2021;16:e0249223. [PMID: 33793621 DOI: 10.1371/journal.pone.0249223] [Reference Citation Analysis]
100 Watt GP, De La Cerda I, Pan JJ, Fallon MB, Beretta L, Loomba R, Lee M, McCormick JB, Fisher-Hoch SP. Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. Hepatol Commun 2020;4:1793-801. [PMID: 33305150 DOI: 10.1002/hep4.1603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Kosasih S, Zhi Qin W, Abdul Rani R, Abd Hamid N, Chai Soon N, Azhar Shah S, Yaakob Y, Raja Ali RA. Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease. Int J Hepatol 2018;2018:9252536. [PMID: 30363686 DOI: 10.1155/2018/9252536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
102 Mosca A, Panera N, Crudele A, Alisi A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert Review of Gastroenterology & Hepatology 2020;14:1035-46. [DOI: 10.1080/17474124.2020.1801413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
103 Mikolasevic I, Domislovic V, Klapan M, Juric T, Lukic A, Krznaric-Zrnic I, Fuckar-Cupic D, Stimac D, Filipec Kanizaj T, Krznaric Z, Radic-Kristo D, Milic S, Martinovic M, Grubesic A, Grgurevic I. Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol 2021;47:428-37. [PMID: 33358052 DOI: 10.1016/j.ultrasmedbio.2020.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Frankowski M, Świerkot J, Gomułkiewicz M, Korman L, Skoczyńska M, Starba A. Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. Rheumatol Int 2021. [PMID: 34870735 DOI: 10.1007/s00296-021-05059-z] [Reference Citation Analysis]
105 Broering D, Shawkat M, Albenmousa A, Abaalkhail F, Alabbad S, Al-Hamoudi W, Alghamdi S, Alqahthani S, Jaafari A, Troisi R, Bzeizi K. Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors. PLoS One 2021;16:e0251487. [PMID: 33984017 DOI: 10.1371/journal.pone.0251487] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Hirono H, Watanabe K, Hasegawa K, Ohkoshi S. Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population. J Clin Transl Hepatol 2019;7:127-31. [PMID: 31293912 DOI: 10.14218/JCTH.2018.00048] [Reference Citation Analysis]
107 Taibbi A, Petta S, Matranga D, Caruana G, Cannella R, Busè G, Marco VD, Midiri M, Bartolotta TV. Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. Ultrasonography 2021;40:407-16. [PMID: 33561928 DOI: 10.14366/usg.20147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol 2019;15:e8793. [PMID: 30824564 DOI: 10.15252/msb.20188793] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
109 Schaapman JJ, Tushuizen ME, Coenraad MJ, Lamb HJ. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. J Magn Reson Imaging 2021;53:1623-31. [PMID: 32822095 DOI: 10.1002/jmri.27292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
110 Darvish Damavandi R, Shidfar F, Najafi M, Janani L, Masoodi M, Akbari-Fakhrabadi M, Dehnad A. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. Phytother Res 2021;35:3145-56. [PMID: 33880813 DOI: 10.1002/ptr.6972] [Reference Citation Analysis]